榛花消肾安胶囊对糖尿病肾病患者血清C-反应蛋白、肿瘤坏死因子-α和尿单核细胞趋化蛋白-1的影响

发布时间：2019-07-09 13:41

【摘要】：目的:榛花消肾安胶囊对糖尿病肾病患者血清C-反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和尿单核细胞趋化蛋白-1(MCP-1)水平的影响。方法:将2014年5月—2016年5月本院收治的96例糖尿病肾病患者按其临床治疗方法分成A组、B组和C组,每组32例,A组患者予降糖、控制饮食、降低氧化应激等常规基础治疗上予以西药缬沙坦胶囊口服治疗,B组患者在常规治疗基础上予以中成药榛花消肾安胶囊口服治疗,C组患者在B组基础上联合加用西药缬沙坦胶囊口服治疗,比较3组患者的临床疗效及临床炎症相关指标水平的变化。结果:(1)3组患者治疗前其CRP、IL-6、TNF-α和尿MCP-1水平均无明显差异(P0.05),治疗后3组患者CRP、IL-6、TNF-α和尿MCP-1水平较治疗前均降低,且B组和C组降低程度较A组明显,C组较B组降低更甚,比较间均具有统计学意义(P0.05);(2)治疗结束后,B组(81.25%)和C组临床总有效率(93.02%)明显高于A组(62.50%),且C组(96.88%)与B组(81.25%)临床总有效率比较具有统计学意义(P0.05);(3)3组间不良反应发生率比较无统计学意义(P0.05),且无明显严重不良反应事件发生。结论:榛花消肾安胶囊可明显降低DN患者血清hs-CRP、TNF-α和尿MCP-1水平,具有良好的临床疗效及安全性。
[Abstract]:Aim: to study the effect of hazelnut Xiaoshen an capsule on serum C-reactive protein (hs-CRP), tumor necrosis factor-伪 (TNF- 伪) and urinary monocyte chemoattractant protein-1 (MCP-1) in patients with diabetic nephropathy. Methods: from May 2014 to May 2016, 96 patients with diabetic nephropathy were divided into three groups: group A (n = 32), group B (n = 32) and group C (n = 32). Group A was treated with valsartan capsule on the basis of hypoglycemic, diet control and oxidative stress reduction, and group B was treated with hazelnut Xiaoshen capsule, a proprietary Chinese medicine, on the basis of routine treatment. The patients in group C were treated with western medicine valsartan capsule on the basis of group B, and the clinical efficacy and the level of clinical inflammation related indexes were compared among the three groups. Results: (1) there was no significant difference in CRP,IL-6,TNF- 伪 and urine MCP-1 between the three groups before treatment (P 0.05). After treatment, the levels of CRP,IL-6,TNF- 伪 and urine MCP-1 in the three groups were lower than those before treatment, and the decrease in group B and C was significantly lower than that in group A, and the decrease in group C was significantly lower than that in group B (P 0.05). (2) after treatment, the total clinical effective rate of group B (81.5%) and group C (93.02%) was significantly higher than that of group A (62.50%), and the total clinical effective rate of group C (96.88%) was significantly higher than that of group B (8125%) (P 0.05); (3), and there was no significant difference in the incidence of adverse reactions between group C (96.88%) and group B (P 0.05). Conclusion: Hazelnut Hua Xiaoshen an capsule can significantly reduce the levels of serum hs-CRP,TNF- 伪 and urinary MCP-1 in patients with DN, and has good clinical efficacy and safety.
【作者单位】：长春中医药大学;吉林省中医院内分泌科;长春中医药大学附属医院骨伤康复科;
【基金】：吉林省科技发展计划项目(20150204090SF)
【分类号】：R259

【相似文献】